, we treated 378 B-chronic lymphocytic leukaemia (CLL) patients with cladribine (2-CdA), and 255 of the patients were also treated with prednisone. A total of 194 patients were previously untreated, and 184 had relapsed or refractory disease after previous other therapy. Complete response (CR) was obtained in 111 (29´4%) and partial response (PR) in 138 (36´5%) patients, giving an overall response (OR) rate of 65´9%. CR and OR were achieved more frequently in patients in whom 2-CdA was a ®rst-line treatment (45´4% and 82´5% respectively) than in the pretreated group (12´5% and 48´4% respectively) (P < 0´0001). The median duration of OR for previously untreated patients was 14´7 months and for pretreated patients 13´5 months (P 0´09). The median survival evaluated from the beginning of 2-CdA treatment was shorter in the pretreated group (16´3 months) than in the untreated group (19´4 months) (P < 0´0001). A total of 117 (63´9%) patients died in the pretreated group and 63 (32´6%) in the untreated group. In pretreated patients, 2-CdA prednisone (P) and 2-CdA alone resulted in similar OR (51´0% and 45´0% respectively; P 0´4). In contrast, in untreated patients, 2-CdA P produced a higher OR (85´4%) than 2-CdA alone (72´1%) (P 0´04). Infections and fever of unknown origin, observed in 91 (49´4%) pretreated and 74 (38´1%) untreated patients (P 0´03), were the most frequent toxic effects. Our results indicate that 2-CdA is an effective, relatively well-tolerated drug, especially in previously untreated CLL.
vincristine and prednisone) have also been evaluated, giving results generally less superior to those obtained with chlorambucil (Binet & French Co-operative Group on CLL, 1993) .
The newer purine analogues,¯udarabine (FAMP), 2 Hdeoxycoformycin (DCF) and cladribine (2-chlorodeoxyadenosine; 2-CdA) have been synthesized recently and introduced for the treatment of low-grade lymphoid malignancies, including CLL (Carrera et al, 1994) . In single-arm uncontrolled studies, high response rates have been reported with both FAMP (Keating et al, 1989; Robertson et al, 1992; Sorensen et al, 1997) and 2-CdA (Piro et al, 1989; Juliusson & Liliemark, 1993; Robak et al, 1996) in previously treated and untreated patients. The results of the studies presented so far have shown that FAMP and 2-CdA give similar complete remission and overall response rates, but the in¯uence of these drugs on survival time is still uncertain, and there are no studies directly comparing 2-CdA and FAMP (Cheson, 1998) . The preliminary results from a large randomized study comparing FAMP and chlorambucil in previously untreated patients showed a higher complete remission (CR) rate and overall response (OR) rate for FAMP (27% and 70% respectively) than for chlorambucil (3% and 45% respectively) (Rai et al, 1996) . A higher response rate to FAMP in comparison with CAP (cyclophosphamide, doxorubicin and prednisone) was also observed in both untreated (71% vs. 60%; P 0´26) and pretreated (48 vs. 27%; P 0´036) patients in a multicentre prospective randomized trial (Johnson et al, 1996) . In addition, when used as a ®rst-line therapy, udarabine has given a signi®cant prolongation of remission, compared with alkylating agent chemotherapy. However, as yet, no improvement in overall survival has been observed when FAMP was used as ®rst-line therapy in patients with previously untreated CLL.
The preliminary results of our randomized multicentre study also indicated that 2-CdA in combination with prednisone as a ®rst-line therapy gave a higher CR rate (37%) and OR rate (81%) than chlorambucil with prednisone (6% and 46% respectively) (Robak et al, 1998) . However, the evaluation of the in¯uence of both regimens on survival time needs further observation and longer clinical follow-up. Long-term follow-up of patients with CLL receiving FAMP as initial therapy has been reported recently by Keating et al (1998) . The overall response rate was 78%, and the median survival was 63 months. In this report, we present the updated results of the treatment with 2-CdA with or without prednisone (P) of a large cohort of 378 patients with B-CLL, previously treated and untreated, observed in our institutions for the last 7 years. 
PATIENTS AND METHODS
Patients. Between January 1992 and January 1999, 378 patients with progressive or symptomatic CLL were treated with 2-CdA in 10 haematological centres in Poland. The characteristics of the patients are presented in Table I . All the patients ful®lled the National Cancer Institute Sponsored Working Group diagnostic criteria for CLL (Cheson et al, 1988 . There were 257 men and 121 women with a median age of 57´0 years (range 27±92 years). Pretreatment evaluation included medical history, physical examination, complete blood cell count, differential count, bone marrow examination and chemical survey. All patients had documented lymphocytosis with an absolute lymphocyte count greater than 10´10 9 /l and more than 30% lymphocytes in the normal or hypercellular bone marrow. Cell marker studies were performed to con®rm B-cell origin and monoclonal proliferation. We used monoclonal antibodies manufactured by Dako, Denmark, and two-colour¯ow cytometry (Coulter, Hialeah, FL, USA). Immunologically, all patients were CD5, CD19, CD20 and CD23 positive and showed monoclonality for light chain immunoglobulin membrane surface receptors.
The clinical stage of disease was determined at the time of initiation of 2-CdA treatment according to Rai's classi®ca-tion (Rai et al, 1975) . The distribution is shown in Table I . A total of 216 (57´1%) patients with Rai stage III or IV were included in the study. Patients with stage 0, I or II were eligible if they had evidence of active disease, including progressive lymphocytosis, massive splenomegaly or bulky lymphadenopathy, recurrent disease-related infections, weight loss > 10% over a 6-month period, fever above 388C related to disease or extreme fatigue. At the beginning of therapy, they had normal renal (creatinine < 88´4 mmol/l) and hepatic (bilirubin < 17´1 mmol/l) functions and were free of active infections. In all, 194 (51´3%) patients were newly diagnosed or previously untreated and given 2-CdA because of progressive disease, whereas 184 (48´7%) patients had been treated previously with chlorambucil and prednisone followed by polychemotherapy according to COP (51 patients) or CHOP (37 patients) schedules when they relapsed or were refractory to an alkylating agent. Autoimmune haemolytic anaemia (AIHA) with Coombs positive test was diagnosed in 26 (6´9%) patients. In two patients, pure red cell aplasia (PRCA) was noted. Seventy-nine (21%) patients had a history of prior infection. The median time from diagnosis to 2-CdA treatment was 12´1 (range 0±114) months in the untreated group and 42´3 (range 3±198) months in the pretreated group. The study was approved by the local ethics committees, and the patients had given informed consent.
Treatment modality. Cladribine was initially supplied by the Foundation for the Development of Diagnostics and Therapy (Warsaw) and, from January 1998, was obtained commercially (Biodribin, Institute of Biotechnology and Antibiotics, Warsaw, Poland). The drug was synthesized using the method of Kazimierczuk et al (1984) . 2-CdA was administered at a dose of 0´12 mg/kg/day by 2-h intravenous infusions for 5 consecutive days. A total of 255 (67´5%) patients received prednisone 30 mg/m 2 orally each day for 5 days starting with 2-CdA courses. 2-CdA alone was used in the patients treated in three centres, and 2-CdA was combined with prednisone in seven centres. The cycles were usually repeated at monthly intervals. If severe infections or progressive, drug-induced cytopenia developed (thrombocytopenia < 50´10 9 /l and/or neutropenia < 1´0´10 9 /l), 2-CdA therapy was stopped until the haematological parameters increased. The drug was then readministered. In such cases, time intervals between 2-CdA cycles ranged from 2 to 6 months.
If a complete response was achieved, no further 2-CdA treatment was administered. In the case of incomplete but continuous partial response (PR), up to six cycles were given. The treatment with 2-CdA was discontinued if no response (NR) was achieved after three courses.
Non-responders and patients who relapsed earlier than 12 months after completing the treatment received an alternative therapy (chlorambucil with prednisone or CHOP therapy). Ten patients who were refractory to 2-CdA treatment were then treated with FAMP at a dose of 25± 30 mg/m 2 /day for 5 days every 4 weeks. Patients who relapsed later than 12 months received retreatment with 2-CdA according to the same mode as the ®rst 2-CdA therapy. In the patients in whom AIHA or progressive thrombocytopenia developed during 2-CdA treatment, administration of this drug was also stopped, and prednisone at an initial dose of 0´5±1´0 mg/kg was introduced.
Packed red blood cells were transfused for symptomatic anaemia or prophylactically if the haemoglobin level was lower than 7´0 g/dl. Platelets were administered prophylactically if the platelet count was less than 15´0´10 9 /l. In order to prevent hyperuricaemia, allopurinol (300 mg/day) was given routinely. No patients received antibiotics prophylactically.
Response criteria. Physical examination and peripheral blood analysis were performed before and after every 2-CdA course, and the response to the drug was estimated. Bone marrow biopsy and, in some cases, immunophenotypic analysis were performed to con®rm complete remission after every two or three courses of 2-CdA. Guidelines for response evaluation were those developed by the NCI ± Sponsored Working Group (Cheson et al, 1988 . Complete response (CR) required the absence of symptoms and organomegaly, a normal complete blood cell count (absolute neutrophil count > 1´10 9 /l, haemoglobin concentration > 11´0 g/l, platelet count > 100´10 9 /l) and bone marrow with less than 30% lymphocytes for at least 2 months. Partial response (PR) was considered in the case of a 50% or greater decrease in the size of lymph nodes, liver and spleen, and peripheral blood ®ndings either identical to those of CR or improved over pretherapy values by at least 50%. No bone marrow evaluation was required for determination of PR. The patients who did not achieve CR or PR were classi®ed as non-responders (NR). Clinical relapse was de®ned according to Robertson et al (1992) as an increase in the absolute lymphocyte count above 10´10 lymph nodes, appearance of palpable hepatosplenomegaly or development of an aggressive lymphoma.
Toxicity monitoring. Haematological toxicity was evaluated according to the NCI ± Sponsored Working Group criteria. 2-CdA-induced anaemia, thrombocytopenia and neutropenia were considered if, after the treatment course, a further decrease in haemoglobin level and/or platelet and neutrophil numbers were observed. Other side-effects were monitored and assessed according to standard criteria (Oken et al, 1982) . The blood counts, creatinine, bilirubin, GOT, GPT, ECG, urinalysis and general physical examination were serially evaluated and recorded.
Only major and moderate infections were recorded, including life-threatening episodes, such as pneumonia, meningitis and disseminated infections that required oral or parenteral antibiotic therapy, antifungal therapy and/or hospitalization. Fever of unknown origin (FUO) was also recorded as an infection event. Mild infections requiring no therapy or topical therapy were not analysed.
Immunophenotype analysis. Immunophenotyping was performed before treatment on peripheral blood and/or bone marrow by¯ow cytometry using a simultaneous dual-colour staining technique. In some responsive patients, immunophenotyping was repeated after three and six courses and then every 6 months. Blood was collected in vacuum tubes with EDTA as anticoagulant. Bone marrow cells were aspirated from the dorsal iliac crest and immediately put into heparinized tubes. Flow cytometry analyses were performed by FACS scan (Coulter, Hialeah, FL, USA). A combination of phycoerythrin (PE)-and¯uorescein isothiocyanate (FITC)-conjugated monoclonal antibodies was used. Residual disease was determined by co-expression of CD5 and CD19 on B lymphocytes in conjunction with monoclonality of surface light chain expression on CD5-positive B cells. The presence of more than 10% of the total lymphocytic population co-expressing CD19 and CD5 with monotypic light chain expression was considered positive for residual disease according to criteria developed by Robertson et al (1992) A k:l or l:k ratio exceeding 3:1 was considered as monotypic light chain expression Brugiatelli et al, 1997) .
Statistical analysis. The statistical analysis of the difference in percentage of patient responses and 2-CdA toxicity was evaluated by the chi-squared test at the P < 0´05 level of con®dence. Progression-free survival and overall survival curves were calculated using the method of Kaplan & Meier (1958) and compared between groups using the log-rank test. Progression-free survival (PFS) was calculated from the achievement of CR or PR after 2-CdA therapy to the time of relapse. The survival time was measured from the day of ®rst treatment with any regimen as well as from the start of 2-CdA to death from any cause or last observation.
RESULTS

Response to therapy
The response characteristics to 2-CdA regimens in previously treated patients are shown in Table II and in  untreated patients in Table III . The median time from diagnosis to 2-CdA administration was 12´1 months (range 0±114 months) if it was a ®rst-line regimen and 42´3 months (3±198 months) in previously treated patients (Table I ). In the analysed group of 378 patients, CR was obtained in 111 (29´4%) and PR in 138 (36´5%) patients, giving an overall response rate of 65´9%. Overall, 129 patients (34´1%) did not respond to 2-CdA.
Overall response was obtained in 89 out of 184 (48´4%) previously treated patients and in 160 out of 194 (82´5%) patients in the untreated group (P < 0´0001). CR was obtained in 23 (12´5%) and PR in 66 (35´9%) patients treated before the administration of 2-CdA. In the previously untreated group, CR was observed in 88 (45´4%) patients and PR in 72 (37´1%) patients (P < 0´0001). CR and overall responses (OR) were achieved more frequently in the patients in whom 2-CdA was a ®rst-line treatment than in pretreated patients (P < 0´0001). The percentages of PR were similar in both groups (P > 0´05). In the group of 184 previously treated patients, 87 had received one regimen and 97 two or more regimens before 2-CdA treatment. The OR rate in the patients who received only chlorambucil and prednisone was similar to the OR rate in the patients treated with two or more other regimens before 2-CdA (51´7% and 44´9% respectively; P 0´3). Surface immunophenotyping by¯ow cytometry using two-colour staining of peripheral blood and/or bone marrow mononuclear cells was performed in only 76 patients who responded to 2-CdA therapy and achieved CR. Residual disease was demonstrated in 51 (67´1%) patients. The median duration of OR (CR PR) was 14´7 months for previously untreated patients (range 3± 54 months) and 13´5 months (range 3±69 months) for patients previously treated with one or more regimens (P 0´009). The median duration of CR was similar in untreated patients (16´9 months, range 3±54 months) and in the pretreated group (15´0 months, range 1±72 months) (P 0´7). The median duration of CR was longer than PR in both the previously treated and the untreated group (Fig 1) . The median survival duration evaluated from the beginning of 2-CdA treatment was shorter in the pretreated group (16´3 months, range 1±72 months) than in the untreated group (19´4 months, range 1±60 months; P < 0´0001; Fig  2) . The median survival time measured from the introduction of the ®rst treatment regimen was 54´0 (range 4±228) months and 19´6 (range 1±60) months respectively (P < 0´0001; Fig 2) . In the pretreated group, 117 out of 184 (63´9%) patients died and, in the untreated group, 63 (32´6%) out of 194 patients died (P 0´001). The in¯uence of the previously used regimens on the survival time is dif®cult to evaluate because of the short observation time of the patients who received only one regimen before 2-CdA courses. The median survival was longer in patients who responded (CR or PR) to 2-CdA treatment than in nonresponders in both the pretreated and the previously untreated group (Fig 3) . untreated patients was higher in the group treated with 2-CdA and prednisone (85´4%) than in the group treated only with 2-CdA (72´1%)) (P 0´04). In contrast, the overall response rates in treated patients were not signi®cantly different (51´0% and 45´0% respectively) (P 0´4). There is also no signi®cant difference in survival time in patients treated with 2-CdA alone or with 2-CdA and prednisone in previously untreated patients (Fig 4) . In contrast, the median survival time of previously treated patients was longer in the group treated with 2-CdA plus prednisone than in the group that received 2-CdA without prednisone (P = 0´001) (Fig 4) .
In¯uence of age on response and survival
We analysed the in¯uence of patient age on the effect of 2-CdA regimens. The OR rates in the patients older than 70 years, 55±70 years and younger than 55 years were not statistically different in both previously treated and untreated groups (P > 0´05). (Tables II and III) . The survival time was also similar in all three analysed age groups of untreated patients (P > 0´05). However, in the pretreated group, the survival time was longer in the patients younger than 55 years (median 66´3 months) than in the patients aged 55±70 years (median 59´1 months) and older than 70 years (median 36´9 months; P 0´01).
The in¯uence of Rai stage on response and survival
In the previously treated group, OR rate was higher in patients in stages I and II than in stages III and IV (62´5% and 42´2% respectively; P 0´01). However, there was no signi®cant difference in survival time in both groups (52´6 and 64´6 months respectively; P 0´5; Fig 5) . In previously untreated patients, the OR rate in patients with Rai stages I and II was also higher than in Rai stages III and IV (92´9% and 70´4% respectively; P 0´0001). Median survival time was longer in patients with Rai stage 0 and Rai stages I and II than in Rai stages III and IV (45´5, 32´3 and 27´8 months respectively; P < 0´0001; Fig 5) .
Response to treatment with 2-CdA and other treatment regimens in refractory or relapsed patients Thirty-®ve patients who were refractory to 2-CdA treatment or relapsed sooner than 12 months after completing the treatment were treated with chlorambucil (12 mg/m 2 ) combined with prednisone (30 mg/m 2 /day) for 7 consecutive days (Table IV) . The regimen was repeated every 28 days. In the untreated group, CR was achieved in one (4%) patient and PR in seven (28%) patients, giving an overall response rate of 32%. In the pretreated group, only two (20%) out of 10 patients achieved PR. The median duration of response was 3´4 months (range 3±30 months). Ten other pretreated patients received FAMP at a dose of 25± 30 mg/m 2 /day for 5 days. In only two (20%) of them was a PR achieved.
Twenty-eight patients who relapsed later than 12 months after 2-CdA treatment received 2-CdA again at the same doses as in ®rst-line therapy. CR was achieved in ®ve (17´8%) patients and PR in ®ve (17´8%) patients, giving an overall response rate of 35´6%. Fifty-six patients who failed to respond to 2-CdA and chlorambucil treatment were treated according to the COP and/or CHOP regimens. Only ®ve (9´1%) of them responded to such therapy.
Side-effects and mortality
Toxicity of 2-CdA in the patients previously treated as well as in the untreated group is presented in Table V. The most frequent undesirable effect was thrombocytopenia noted in 61 (33´1%) pretreated and 51 (26´2%) previously untreated patients (P 0´4). Twenty-two patients required platelet transfusion, and 10 died because of bleeding. Drug-related neutropenia was noted in 41 (22´3%) of the previously treated and 40 (20´6%) untreated patients (P 0´7) In 10 of them, therapy with haematopoietic growth factors (G-CSF or GM-CSF) was introduced. Infections and fever of unknown origin were observed more frequently in previously treated (91 patients, 49´4%) than in untreated patients (74 patients, 38´1%; P 0´03). Infection complications occurred in 92 (36%) out of 255 patients receiving 2-CdA with prednisone and in 72 (58%) out of 123 patients who received 2-CdA alone (P 0´8). The most frequent complications were pneumonia as well as upper respiratory, sinus and bronchial infections, which occurred in 16 (20%) pretreated and 25 (37%) untreated patients. Meningitis caused by Neisseria meningitidis was diagnosed in one patient. Episodes of herpes zoster reactivation and herpes simplex infections were observed in 21 (20%) pretreated and in 22 (25%) untreated patients. Fungal pulmonary infections were diagnosed in three (4%) pretreated and in nine (7%) untreated patients. No infections caused by Listeria monocytogenes and Pneumocystis carini pneumonia were noted. However, tuberculosis was recognized in three untreated patients and in one pretreated patient. Four episodes of fever of unknown origin were noted in the patients.
Autoimmune haemolytic anaemia (AIHA) during or after 2-CdA therapy was observed in seven (3´8%) patients in the previously treated group and in seven (3´6%) patients in the previously untreated group (P 0´9). AIHA was successfully treated with prednisone in 10 patients, and four were refractory to such treatment. Pure red cell aplasia (PRCA) during 2-CdA treatment was seen in one pretreated patient and in four (2´1%) patients in the untreated group (P 0´07). Skin lesions were found in 12 (3´2%) patients, and they appeared during or up to 2 weeks after the 2-CdA course. In the majority of patients, skin changes were disseminated, strongly itching and cleared after the administration of oral antihistaminic drugs and/or corticosteroids.
During data collection, 180 out of 378 patients (47´6%) died; 63 (32´3%) in the previously untreated group and 117 (63´6%) in the pretreated group. The causes of death are shown in Table VI . Infections were the most frequent cause of death in both groups: 49 patients died of pulmonary infection, and 46 of septic shock. Eighteen patients died of haemorrhage, ®ve of cardiovascular complications, 20 of disease progression and two of second malignancy.
DISCUSSION
New purine analogues, FAMP and 2-CdA, have been examined intensively in CLL patients for more than 10 years, but their place in standard management has not yet been established. To our knowledge, the presented group of 378 patients with B-CLL is the largest analysed in the literature so far, and the 7-year period of observation is relatively long (Bergman, 1997; Cheson, 1998) . We administered 2-CdA both as a ®rst-line therapy and to patients previously treated with other regimens. The results of our studies indicate that 2-CdA may give a signi®cant percentage of complete and partial responses, both in patients previously treated with chlorambucil and prednisone, and also in some treated with COP and CHOP, as well as in untreated patients. However, the percentage of overall responses and complete remissions was greater when 2-CdA was used as ®rst-line therapy (82´5% and 45´1% respectively) than in previously treated patients (48´4% and 12´5% respectively). These results are consistent with our previous observations (Robak et al, 1996) , as well as with data presented by other authors (Delannoy et al, 1995 , Saven et al, 1995 Juliusson & Liliemark, 1996) .
The monitoring of minimal residual disease (MRD) is especially important in younger patients treated with new purine analogues in order to qualify them for bone marrow transplantation, thus offering them the possibility of recovery. Using monoclonal antibodies and the¯uores-cence-associated cell sorting (FACS) technique, we assessed MRD in 76 CLL patients who achieved a CR according to haematological criteria. Immunophenotypical remission according to the criteria proposed by Brugiatelli et al (1997) was noted only in 25 (32´9%) patients treated with 2-CdA. A higher percentage of immunophenotypical remission was observed by Robertson et al (1992) in CLL patients treated with FAMP, who reported a complete eradication of leukaemic clones in 89% in CR and in only 19% of patients in PR according to haematological criteria.
More than half of our patients received 2-CdA together with prednisone (56´5% previously treated and 77´1% untreated). In the group of previously treated patients, the OR rate after treatment with 2-CdA alone and with 2-CdA combined with prednisone did not differ signi®cantly (45% and 51% respectively; P 0´4), and response duration was also similar (5´8 and 6´6 months respectively). However, it should be emphasized that the survival time of pretreated patients treated with 2-CdA and prednisone was signi®cantly longer than that of patients treated with 2-CdA alone (P 0´001). The response rate in previously untreated patients receiving 2-CdA and prednisone was higher (85´4%) than in the group receiving 2-CdA alone (72´1%; P 0´04). In our previous studies, we did not ®nd differences between the response rate in patients treated with 2-CdA and prednisone and that in patients treated with 2-CdA alone but, in patients receiving 2-CdA and prednisone, response was obtained after the administration of fewer cycles (Robak et al, 1997a) . Prednisone given alone has only modest effects on the primary treatment of CLL (Ezdinli et al, 1969) . In some studies, combining chlorambucil and prednisone has given a greater response rate than administering chlorambucil alone (Han et al, 1973) . However, signi®cant bene®ts have not been observed after the combination of prednisone with FAMP in both previously treated and untreated patients O'Brien et al, 1993a,b; Keating et al, 1998) . Moreover, there is a possibility that the combination of prednisone with purine analogues will fortify their immunosuppressive activity and increase the risk of infections, especially opportunistic ones (Anaissie et al, 1992) . On the other hand, corticosteroids alone may improve bone marrow function and facilitate subsequent treatment with cytotoxic agents (Catovsky et al, 1989) .
Old age is an unfavourable prognostic factor in CLL patients (Catovsky et al, 1989) . However, in pretreated patients, we did not observe any signi®cant differences in total response rate and in response duration in patients over 70 years of age, between 70 and 55 years, and below 55 years. Nevertheless, survival time was shorter in older than in younger patients. In patients below 55 years of age, in whom 2-CdA was ®rst-line therapy, the response rate was greater than in older patients (P 0´007), and response duration and survival were longer in younger than in older patients. Our results are in agreement with the observations of Keating et al (1993 Keating et al ( , 1998 , based upon retrospective analysis of patients treated with FAMP, that old age was an unfavourable prognostic factor in both previously treated and untreated patients.
Clinical stages are among the most useful prognostic indicators (Montserrat & Rozman, 1993) . In our studies, we found greater response rate and longer response and survival duration in patients in Rai stages I and II than in stages III and IV in untreated patients, and the differences were statistically signi®cant. Similar associations were observed in patients treated with other agents, including FAMP (Rai et al, 1975; Keating et al, 1998) . Our studies con®rmed the results of previous observations that the intensity and ef®ciency of previous treatment has a great in¯uence on the ef®cacy of treatment with the new purine analogues. 2-CdA was the most ef®cient agent as regards response rate, including complete remission, response duration and survival rate, when administered as a ®rst-line therapy (Bergman, 1997; Cheson, 1998) . However, it should be noted that survival rate calculated from the beginning of any treatment was even shorter when 2-CdA was the ®rst-line treatment in comparison with patients in whom this drug was used as a second-or even third-line treatment. It may be explained, at least in part, by the observation that patients who are refractory to purine analogues generally fail to respond to alkylating agent-based regimens. Despite the fact that these studies are of a retrospective nature, they may con®rm preliminary results of randomized trials comparing the ef®cacy of treatment with 2-CdA or FAMP with conventional chemotherapy (Johnson et al, 1996; Rai et al, 1996; Robak et al, 1998) . It was revealed in these studies that, despite the fact that the new purine analogues give greater CR and OR rates than conventional chemotherapy, it has not been established so far whether they have any in¯uence on survival time.
In the present study, we also evaluated the ef®cacy of chlorambucil and prednisone as well as FAMP in patients in whom 2-CdA was inef®cient as a ®rst-line treatment. Our results may indicate that cross-resistance between 2-CdA and alkylating agents as well as between 2-CdA and FAMP exists in the majority of patients. Although Juliusson et al (1992) obtained response to 2-CdA in four patients previously unresponsive to FAMP, O'Brien et al (1994) found cross-resistance between these two agents in a larger group of patients. Our studies also indicate the presence of cross-resistance when 2-CdA is used as a ®rst-line therapy and FAMP as a second-line therapy. Retreatment with 2-CdA in patients who relapsed after successful primary therapy with this drug was applied in 28 patients, leading to complete or partial response in 10 of them (35´6%). The ef®cacy of 2-CdA with repeated treatment was also observed by Juliusson & Liliemark (1994) , who obtained another response in all six patients treated by them. However, these authors observed a greater myelosuppressive effect of 2-CdA with repeated treatment than during primary therapy.
The results of our study indicate that 2-CdA is a welltolerated agent, especially in previously untreated patients. The most commonly observed adverse effect was thrombocytopenia, which was observed in 33´1% of pretreated and in 26´2% of untreated patients (P 0´04). Haemorrhage associated with thrombocytopenia was a cause of death in 10 patients, including seven pretreated patients. These observations indicate the necessity of maintaining great caution in the administration of 2-CdA, especially in heavily pretreated patients, in order to perform platelet transfusion in case of severe thrombocytopenia and haemorrhagic diathesis. Neutropenia was observed in 22´3% and 20´6% of patients respectively (P 0´7). Treatment-induced granulocytopenia constituted a signi®cant clinical problem in over 20% of patients. We applied haematopoietic growth factors (G-CSF or GM-CSF) only in several patients, and this was not analysed in the present study. However, the observations of other authors indicate that these agents may be useful in CLL patients with neutropenia induced by FAMP and other cytotoxic agents (Itala et al, 1997; O'Brien et al, 1997) .
Infections were the most common side-effect in our patients in the pretreated (49´4%) as well as in the untreated (38´1%) groups and constituted the most frequent cause of death. The problem of common occurrence of life-threatening infections in CLL patients treated with purine analogues has been noted and analysed before in patients treated with 2-CdA as well as with FAMP (Van den Neste et al, 1996; Anaissie et al, 1998) . It should be emphasized that the occurrence of opportunistic infections may be associated with T-cell dysfunction. The association of the more common occurrence of bacterial and viral infections with lymphopenia or neutropenia is more controversial and not so well documented (Van den Neste et al, 1996; Betticher et al, 1998) .
Autoimmune haemolytic anaemia (AIHA) developed in 3´7% of patients treated with 2-CdA, and this percentage was similar in pretreated and untreated patients. Previous studies demonstrated that AIHA may occur in some CLL patients treated with both FAMP and 2-CdA (Di Raimondo et al, 1993; Robak et al, 1997b) . The mechanism of this phenomenon has not been explained so far. It is assumed that purine analogues might intensify deregulation of the immune system in the course of this disease, especially suppression of CD4 lymphocytes. On the other hand, we observed resolution of haemolytic symptoms in some CLL patients with co-existing AIHA after administering 2-CdA, as analysed in our previous study (Robak et al, 1997b) .
In conclusion, the results of our study indicate that 2-CdA is an effective and relatively well-tolerated drug, especially in previously untreated CLL. However, the in¯uence of this agent on overall survival time is still uncertain. Therefore, we suggest that 2-CdA should be used as a second-line treatment until the results of ongoing randomized clinical trials are available.
